 |
TOKYO, April 1, 2025 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte growth factor (KGF). This product will be on the market beginning April 2025.
Development of Synthetic Peptide Growth Factors by PeptiGrowth
Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products face various quality challenges such as lot-to-lot variation, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that can address these challenges while maintaining equivalent function to the conventional growth factors and cytokines on the market. Our peptides are completely chemically synthesized and animal component-free, enabling xeno-free and chemically defined cell culture media.
About KGF alternative peptide (FGFR2b agonist) [Product code: PG-012]
- Mechanism of activating FGFR2b by the KGF alternative peptide (PG-012)
PG-012, KGF alternative peptide, is a dimeric peptide composed of cyclic peptides designed to bind specifically to FGFR2b. Like KGF, PG-012 effectively interacts with FGFR2b and exhibits agonistic activity against FGFR2b (see diagram below).
- Comparable signal activation activity to recombinant KGF
We conducted a comparative study on the functions of KGF alternative peptide (PG-012) and commercially available recombinant KGF using FGFR2b-overexpressing BaF3 cells. We confirmed that the KGF alternative peptide activates ERK (upper left figure) and exhibits proliferation activity (upper right figure) in a manner similar to recombinant KGF at lower concentrations (ng/mL basis).
We anticipate that the KGF alternative peptide (PG-012) will be applicable in regenerative medicine and cell therapy, particularly in applications such as differentiation and proliferation of epidermal cells and cells derived from the endoderm, such as alveolar epithelial cells, islet cells, and hepatocytes, from pluripotent stem cells.
Product name: KGF alternative peptide (FGFR2b agonist)
Product code: PG-012
Product form: Lyophilized
Storage conditions: -20°C or less
Purity: ≥95% by HPLC
Molecular weight: 6018.40 (Acetate)
Size: 10 μg, 100 μg, 1 mg (volume per vial)
*This product can be provided with an Animal Component Free (ACF) certificate.
*This product is for testing and research use only (RUO).
*There is a possibility that the specifications can change.
If you would like to purchase our products, please contact us using the information below.
For customers who would like to purchase GMP compliant products as well as the above PG products in bulk scale, please contact us using the information below.
Contact Information
PeptiGrowth Inc.
Tel: + 81-(0)70-7789-3905
E-mail: contact@peptigrowth.com
Development of other peptides from PeptiGrowth
We have developed alternative peptides targeting numerous growth factors and cytokines. To date, we have launched 12 products and plan to launch additional growth-factor alternative peptides targeting PDGF-AA and IL-15 by the end of 2025.
TOKYO, April 1, 2025 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte growth factor (KGF). This product will be on the market beginning April 2025.
Development of Synthetic Peptide Growth Factors by PeptiGrowth
Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products face various quality challenges such as lot-to-lot variation, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that can address these challenges while maintaining equivalent function to the conventional growth factors and cytokines on the market. Our peptides are completely chemically synthesized and animal component-free, enabling xeno-free and chemically defined cell culture media.
About KGF alternative peptide (FGFR2b agonist) [Product code: PG-012]
- Mechanism of activating FGFR2b by the KGF alternative peptide (PG-012)
PG-012, KGF alternative peptide, is a dimeric peptide composed of cyclic peptides designed to bind specifically to FGFR2b. Like KGF, PG-012 effectively interacts with FGFR2b and exhibits agonistic activity against FGFR2b (see diagram below).
- Comparable signal activation activity to recombinant KGF
We conducted a comparative study on the functions of KGF alternative peptide (PG-012) and commercially available recombinant KGF using FGFR2b-overexpressing BaF3 cells. We confirmed that the KGF alternative peptide activates ERK (upper left figure) and exhibits proliferation activity (upper right figure) in a manner similar to recombinant KGF at lower concentrations (ng/mL basis).
We anticipate that the KGF alternative peptide (PG-012) will be applicable in regenerative medicine and cell therapy, particularly in applications such as differentiation and proliferation of epidermal cells and cells derived from the endoderm, such as alveolar epithelial cells, islet cells, and hepatocytes, from pluripotent stem cells.
Product name: KGF alternative peptide (FGFR2b agonist)
Product code: PG-012
Product form: Lyophilized
Storage conditions: -20°C or less
Purity: ≥95% by HPLC
Molecular weight: 6018.40 (Acetate)
Size: 10 μg, 100 μg, 1 mg (volume per vial)
*This product can be provided with an Animal Component Free (ACF) certificate.
*This product is for testing and research use only (RUO).
*There is a possibility that the specifications can change.
If you would like to purchase our products, please contact us using the information below.
For customers who would like to purchase GMP compliant products as well as the above PG products in bulk scale, please contact us using the information below.
Contact Information
PeptiGrowth Inc.
Tel: + 81-(0)70-7789-3905
E-mail: contact@peptigrowth.com
Development of other peptides from PeptiGrowth
We have developed alternative peptides targeting numerous growth factors and cytokines. To date, we have launched 12 products and plan to launch additional growth-factor alternative peptides targeting PDGF-AA and IL-15 by the end of 2025.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
BEIJING, Jan. 11, 2026 /PRNewswire/ -- On December 29, the "Forging the Path to National Strength: China's Manufacturing Achievements Under the 14th Five-Year Plan," jointly organized by the National Museum of China and the Ministry of Industry and Information Technology, officially opened at the National Museum of China, showcasing more than 300 top national achievements. GAC's "National Outstanding Engineer Team" successfully developed both the Magazine Battery and the Solid-State Battery, which were selected for the exhibition.
The GAC Magazine Battery is the first battery system to pass both the nail penetration no-flame and non-ignition safety tests. By utilizing ultra-high intrinsic safety cells, an all-weather "vehicle-end + cloud-based" active safety monitoring system, and a multi-dimensional safety protection system, the Magazine Battery achieves three layers of protection: core, active, and passive. Its safety performance far exceeds the electric vehicles traction battery safety requirements (GB38031-2025), which will take effect on July 1, 2026. Currently, the Magazine Battery has a cumulative deployment of 1.3 million vehicles with zero spontaneous combustion and over 50 billion kilometers of safe travel, providing users with robust safety assurance for every journey.
GAC's self-developed large-capacity solid-state battery has achieved an energy density exceeding 400 Wh/kg and easily passes rigorous safety tests such as 200°C thermal chamber and nail penetration tests, effectively addressing users' range anxiety and safety concerns. Innovations in materials and processes have placed the solid-state battery at the forefront of the industry in key indicators such as safety, energy density, and cycle life, providing a superior power solution for the future development of NEVs. Currently, a pilot production line for GAC's solid-state battery has been established, capable of mass-producing vehicle-grade solid-state batteries over 60 Ah, marking a critical step toward the goal of full vehicle integration by 2026.
Over the years, GAC has been steadily enhancing its competitiveness through innovations across intelligent connectivity, NEV powertrains technologies, and forward-looking technologies. Looking ahead, GAC will continue to deepen its efforts in the intelligent connected NEV field, leveraging more leading technological achievements to drive industry progress.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
GAC Magazine Battery and Solid-State Battery Win Top National Honor
